Dr. Parekh on Potential Biomarker for Novel Drug in Myeloma

Samir Parekh, MD
Published: Thursday, Jan 31, 2019



Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.

Selinexor has been tested in patients with various types of cancer, Parekh says, and the overall response rate across all the cancers it has been tested in is about 20%. It seems as though these patients have a molecular characteristic that allow them to respond to this novel drug for an extended period of time, he says, and investigators from Mount Sinai Health System have been working to determine what distinguishes the patients that respond for long period of time from those who don’t.

In a study presented at the 2018 ASH Annual Meeting, patients treated with selinexor were divided into 2 groups: patients with >3 months of response and patients with < 3 months of response. By taking the tumor cells, extracting the RNA and sequencing it, investigators were able determine differences between these 2 groups. Patients with a shorter progression-free survival had a higher level of a protein that is crucial to cell cycle called E2F1, which seems to be associated with resistance to selinexor. These findings need to be confirmed in larger studies, Parekh concludes, but E2F1 can potentially be an important biomarker that can help physicians identify which patients will have better outcomes with the agent.
SELECTED
LANGUAGE


Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.

Selinexor has been tested in patients with various types of cancer, Parekh says, and the overall response rate across all the cancers it has been tested in is about 20%. It seems as though these patients have a molecular characteristic that allow them to respond to this novel drug for an extended period of time, he says, and investigators from Mount Sinai Health System have been working to determine what distinguishes the patients that respond for long period of time from those who don’t.

In a study presented at the 2018 ASH Annual Meeting, patients treated with selinexor were divided into 2 groups: patients with >3 months of response and patients with < 3 months of response. By taking the tumor cells, extracting the RNA and sequencing it, investigators were able determine differences between these 2 groups. Patients with a shorter progression-free survival had a higher level of a protein that is crucial to cell cycle called E2F1, which seems to be associated with resistance to selinexor. These findings need to be confirmed in larger studies, Parekh concludes, but E2F1 can potentially be an important biomarker that can help physicians identify which patients will have better outcomes with the agent.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x